About Variantyx
Variantyx is a company based in Boston (United States) founded in 2014 by Haim Neerman and Tomer Jackman. Variantyx has raised $110.5 million across 6 funding rounds from investors including IBM, Kreos Capital and Bosch Ventures. The company has 122 employees as of December 31, 2022. Variantyx offers products and services including Genomic Unity® 2.0, Exome Plus Analysis, Exome Analysis, and Comprehensive Hereditary Cancer Analysis. Variantyx operates in a competitive market with competitors including Natera, ArcherDX, ImaginAb, Lantern Pharma and RareCyte, among others.
- Headquarter Boston, United States
- Employees 122 as on 31 Dec, 2022
- Founders Haim Neerman, Tomer Jackman
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Variantyx, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$110.5 M (USD)
in 6 rounds
-
Latest Funding Round
$36 M (USD), Series C
Apr 26, 2024
-
Investors
IBM
& 9 more
-
Employee Count
122
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Variantyx
Variantyx offers a comprehensive portfolio of products and services, including Genomic Unity® 2.0, Exome Plus Analysis, Exome Analysis, and Comprehensive Hereditary Cancer Analysis.
Comprehensive analysis for genetic disorders using whole genome sequencing
Targeted genetic testing for specific disorders
In-depth examination of exome for diagnostic purposes
Genetic evaluation for hereditary cancer risks
People of Variantyx
Unlock access to complete
Unlock access to complete
Funding Insights of Variantyx
Variantyx has successfully raised a total of $110.5M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $36 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Variantyx
Variantyx has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include IBM, Kreos Capital and Bosch Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in innovative technology startups.
|
Locked | Locked | Locked | |
|
Venture capital investments in tech and healthtech sectors through dedicated funds.
|
Locked | Locked | Locked | |
|
Early-stage tech startups are funded by the venture capital firm.
|
Locked | Locked | Locked |
Investor details for Variantyx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Variantyx
Investment portfolio details for Variantyx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Variantyx
Detailed financials for Variantyx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Variantyx Comparisons
Peer comparison for Variantyx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Variantyx
Variantyx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, ArcherDX, ImaginAb, Lantern Pharma and RareCyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Drug and companion diagnostics for multi-drug resistant cancers are developed.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
Detailed competitors of Variantyx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Variantyx
Complete news archive for Variantyx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Variantyx
Variantyx was founded in 2014 and raised its 1st funding round 5 years after it was founded.
Variantyx is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Haim Neerman is the current CEO of Variantyx. They have also founded this company.
Variantyx is a funded company, having raised a total of $110.5M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Variantyx is 122.
Variantyx was founded in 2014 and is headquartered in Boston, United States. An integrated platform is provided for the analysis, interpretation, and reporting of next-generation sequencing data in the genomics sector. Whole-genome sequencing data is utilized through partnerships with sequencing providers, followed by automated processing and clinical report generation. Comprehensive molecular diagnostics are delivered for various disease areas in healthcare settings.
Variantyx's top competitors include Natera, ImaginAb and Lantern Pharma.
Variantyx offers Genomic Unity® 2.0, Exome Plus Analysis, Exome Analysis, and Comprehensive Hereditary Cancer Analysis.
Variantyx has 10 investors. Key investors include IBM, Kreos Capital, Bosch Ventures, Pitango, and New Era Capital Partners.